immunotherapy

Research in Review

Immune Checkpoint Inhibitors May Increase Response to CAR-T Therapy in ALL

05/19/2017

JCP Editors

Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...

...

05/19/2017

Journal of Clinical Pathways

Research in Review

PD-L1 Expression Associated With Radiation Resistance in Head and Neck Cancer

05/16/2017

JCP Editors

PD-L1 expression may be a biomarker of local failure in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma following radiotherapy, according to research published in Clinical Cancer Research...

PD-L1...

05/16/2017

Journal of Clinical Pathways

Research in Review

PD-1 Expression in T Cells Aids Immunotherapy Strategies for NSCLC

05/12/2017

JCP Editors

Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to antitumor response for patients with non-small cell lung cancer (NSCLC), according to research published...

Early...

05/12/2017

Journal of Clinical Pathways

Research in Review

Patients With NSCLC Treated With Immunotherapy Likely to Respond to Chemo

05/09/2017

JCP Editors

Patients with advanced non-small cell lung cancer (NSCLC) who undergo salvage chemotherapy are 30% more likely to achieve partial response if they have been treated with a PD-1/PD-L1 checkpoint inhibitor, according...

...

05/09/2017

Journal of Clinical Pathways

Research in Review

PD-1 Expression in T-Cells Aids Immunotherapy Strategies for NSCLC

05/01/2017

JCP Editors

Early activation of programmed cell death-1 (PD-1) in CD8 T-cells after immunotherapy treatment is crucial to anti-tumor response for patients with non-small cell lung cancer (NSCLC), according to research published...

Early...

05/01/2017

Journal of Clinical Pathways

Department

Off-Label Immunotherapy Prescriptions Common, Expensive

04/12/2017

JCP Editors

Many patients receive immunotherapy prescriptions for off-label treatment, potentially contributing to unnecessary health care expenditures.  ----- Related Content Cost-Effective Immunotherapy Treatments for...

Many...

04/12/2017

Journal of Clinical Pathways

Research in Review

B-Cell ALL Disease Burden May Influence CAR T-Cell Therapy Impact on Survival

04/10/2017

JCP Editors

CD19-specific chimeric antigen receptor (CAR) T-cell therapy is more likely to be effective when given immediately after front-line therapy rather than after relapse in certain patients with B-cell acute...

...

04/10/2017

Journal of Clinical Pathways

Research in Review

Maintenance Therapy for MCL Improved by Targeted Drugs

04/10/2017

JCP Editors

Recent advances in targeted therapies have the potential for major impacts on treatment practices for mantle cell lymphoma (MCL), according to a recent review published in Pharmaceuticals...

Recent...

04/10/2017

Journal of Clinical Pathways

Research in Review

Immune Systems Impact Immunotherapy Effectiveness in Head and Neck Cancer

04/05/2017

JCP Editors

Specific immune cells surrounding tumors may play a crucial role in how patients with head and neck cancer respond to nivolumab immunotherapy, according to research presented at the American Association of Cancer...

...

04/05/2017

Journal of Clinical Pathways

Research in Review

Prior Antibiotics May Reduce Immunotherapy Efficacy in Patients With Cancer

02/14/2017

JCP Editors

Patients with cancer who receive antibiotics within a month before beginning their immunotherapy treatment may find the efficacy of their treatment reduced, according to a study that will be presented at the...

...

02/14/2017

Journal of Clinical Pathways